After viewing this presentation the participant will be able to discuss:
• Baseline markers and their relationship to mortality in HIV patients
• Changes in markers following randomisation in the SMART trial
• How changes in markers relate to disease outcome
|
||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||





